Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
General17 hours agoFederal government commits $430 million to prop up Newcastle hydrogen hub
-
Noosa News23 hours agoSix kids charged after shopping centre brawl in Helensvale, Gold Coast
-
General17 hours agoDartbrook coal mine plunges into administration after defaulting on $174 million loan
-
Noosa News21 hours agoStar Casino workers strike in Brisbane amid job uncertainty over looming bankruptcy